August 24th 2022
The panelists conclude their discussion by highlighting investigational agents to look forward to.
Rami Komrokji, MD, presents to the panel a second clinical scenario of a 74-year-old with cytopenic myelofibrosis.
August 18th 2022
A look at the potential treatment options for a patient with myelofibrosis who progresses after first-line therapy.
Key opinion leaders discuss how they would approach treating a 67-year-old with myelofibrosis, presenting with splenomegaly.
August 11th 2022
Drs Palmer and Mesa explain the challenges of treating accelerated phase myeloproliferative neoplasms.
The panel reviews other exciting novel agents under investigation for myelofibrosis treatment.
Ruben Mesa, MD, discusses updates on the novel agent momelotinib from an abstract he presented at ASCO 2022.
Jamile Shammo, MD, FACP, explains the efficacy and safety of the 3 approved therapies for myelofibrosis.
August 3rd 2022
Experts discuss data on the recently approved agents fedratinib and pacritinib for myelofibrosis treatment.
A review of data on the use of the JAK inhibitor ruxolitinib for patients with myelofibrosis.
July 22nd 2022
The panel has a conversation on risk stratification for myelofibrosis and how it individualizes their treatment approaches.
Dr Jamile Shammo explains the process of diagnosing myelofibrosis and highlights the importance of bone marrow biopsies.
July 13th 2022
A discussion on assessing symptom burden and quality of life for patients with essential thrombocythemia or polycythemia vera.
Ruben Mesa, MD, details an abstract presented at ASCO 2022 on an investigational agent filling an unmet need in polycythemia vera.
July 6th 2022
An overview of the treatment options for patients with polycythemia vera.
Jamile Shammo, MD, FACP, FASCP, defines polycythemia vera and explains the process for diagnosis and risk stratification.
June 29th 2022
Dr Ruben Mesa describes how he treats patients with essential thrombocythemia and the available treatment options.
Jeanne Palmer, MD, explains essential thrombocythemia and how it’s diagnosed.
August 4th 2021
A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.
Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.